Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223925 · ClinicalTrials.gov registry record · Phase 2
Maribavir for Prevention of CMV After Stem Cell Transplants
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00223925 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 111 participants.
The verdict
NCT00223925, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.
Interventions
- DRUG Placebo
- DRUG Maribavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2004-10-28 |
| Est. Completion | 2006-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223925
The ClinicalTrials.gov registry entry for NCT00223925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00223925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00223925 about?
NCT00223925 is a clinical study titled "Maribavir for Prevention of CMV After Stem Cell Transplants". Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test ...
What is the current status of trial NCT00223925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2004-10-28. Estimated completion is 2006-04-05.
What interventions are being tested in trial NCT00223925?
The interventions under investigation include: Placebo (DRUG), Maribavir (DRUG).
Who is sponsoring clinical trial NCT00223925?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.